Pharmacology
News
Spinosad: New kid on the block for treating scabies
The formulation “drives the active compound to the stratum corneum, where mites live and breed,” Dr. Anthony J. Mancini said.
News
FDA OKs first drug for Rett syndrome
The drug is designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function.
Conference Coverage
Add-on antipsychotic beats switching meds in older adults with resistant depression
“These results are of great impact for clinicians managing older adults with treatment-resistant depression,” said Dr. Jennifer Gatchel.
Conference Coverage
‘Unheard of’ PAH improvement with novel drug: STELLAR
Sotatercept, a designer molecule that removes a key driver of pulmonary arterial hypertension, had efficacy and safety in the first of three...
News
Once-daily stimulant for ADHD safe, effective at 1 year
The most common Treatment-emergent adverse events during the treatment phase were decreased appetite, upper respiratory tract infection,...
Conference Coverage
Antipsychotic cuts Alzheimer’s-related agitation
Brexpiprazole will become the first drug to be approved for agitation in AD, doctor speculates.
News
Venetoclax shows promise for r/r hairy cell leukemia
Italian study suggests benefits of administering venetoclax for patients with r/r cases of hairy cell leukemia, a rare blood cancer,
Conference Coverage
Phase 3 results: Ponatinib bests imatinib for Ph+ALL
First prospective study of third-generation TKI ponatinib showed its comparative benefit for the most common subtype of adult ALL.
News
Two FDA clearances add diabetes technology options
The FDA has cleared Abbott Freestyle Libre versions 2 and 3 for integration with automated insulin delivery systems and Bigfoot Biomedical’s...
News
Taking a break from TKIs unlikely to shorten survival
The results of a new study showed that taking an occasional respite from TKI therapy had little impact on a patient’s survival.